Literature DB >> 11031258

SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.

M Sattler1, S Verma, Y B Pride, R Salgia, L R Rohrschneider, J D Griffin.   

Abstract

SHIP1 is an SH2 domain containing inositol-5-phosphatase that appears to be a negative regulator of hematopoiesis. The tyrosine kinase oncogene BCR/ABL drastically reduces expression of SHIP1. The major effect of re-expressing SHIP1 in BCR/ABL-transformed cells is reduction of hypermotility. To investigate the potential signaling pathways involving SHIP1 in hematopoietic cells, we overexpressed SHIP1 in a murine BCR/ABL-transformed Ba/F3 cell line and identified SHIP1-associated proteins. SHIP1 was found to form a novel signaling complex with BCR/ABL that includes DOK1 (p62(DOK)), phosphatidylinositol 3-kinase (PI3K), and CRKL, each of which has been previously shown to regulate migration in diverse cell types. We found that DOK1 binds directly through its PTB domain to SHIP1. Direct interaction of SHIP1 with CRKL was mediated through the CRKL-SH2 domain. Co-precipitation experiments suggest that Tyr(917) and Tyr(1020) in SHIP1 are likely to mediate interactions with DOK1. In contrast to wild type SHIP1, expression of tyrosine mutant SHIP1 by transient transfection did not alter migration. PI3K was likely linked to this complex by CRKL. Thus, this complex may serve to generate a very specific set of phosphoinositol products, possibly involved in regulating migration. Overall, these data suggest that proteins that interact with SHIP1 through Tyr(917) and Tyr(1020), such as DOK1 and SHC, are likely to be involved in the regulation of SHIP1 dependent migration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031258     DOI: 10.1074/jbc.M006250200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Authors:  Ian J Griswold; Mary MacPartlin; Thomas Bumm; Valerie L Goss; Thomas O'Hare; Kimberly A Lee; Amie S Corbin; Eric P Stoffregen; Caitlyn Smith; Kara Johnson; Erika M Moseson; Lisa J Wood; Roberto D Polakiewicz; Brian J Druker; Michael W Deininger
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

2.  C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosine-based inhibition motif of FcgammaRIIB and SHIP-1.

Authors:  Keiji Tanigaki; Chieko Mineo; Ivan S Yuhanna; Ken L Chambliss; Michael J Quon; Ezio Bonvini; Philip W Shaul
Journal:  Circ Res       Date:  2009-05-07       Impact factor: 17.367

3.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

4.  Coordinate regulation of residual bone marrow function by paracrine trafficking of AML exosomes.

Authors:  J Huan; N I Hornick; N A Goloviznina; A N Kamimae-Lanning; L L David; P A Wilmarth; T Mori; J R Chevillet; A Narla; C T Roberts; M M Loriaux; B H Chang; P Kurre
Journal:  Leukemia       Date:  2015-06-25       Impact factor: 11.528

5.  SHIP is required for a functional hematopoietic stem cell niche.

Authors:  Amy L Hazen; Michelle J Smith; Caroline Desponts; Oliver Winter; Katrin Moser; William G Kerr
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

6.  IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation.

Authors:  Sanghoon Lee; Charlotte Andrieu; Frédéric Saltel; Olivier Destaing; Jessie Auclair; Véronique Pouchkine; Jocelyne Michelon; Bruno Salaun; Ryuji Kobayashi; Pierre Jurdic; Elliott D Kieff; Bakary S Sylla
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

Review 7.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Authors:  E K Thomas; J A Cancelas; Y Zheng; D A Williams
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

8.  Multimolecular signaling complexes enable Syk-mediated signaling of CD36 internalization.

Authors:  Bryan Heit; Hani Kim; Gabriela Cosío; Diana Castaño; Richard Collins; Clifford A Lowell; Kevin C Kain; William S Trimble; Sergio Grinstein
Journal:  Dev Cell       Date:  2013-02-07       Impact factor: 12.270

9.  Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo.

Authors:  Grant R Stenton; Lloyd F Mackenzie; Patrick Tam; Jennifer L Cross; Curtis Harwig; Jeffrey Raymond; Judy Toews; David Chernoff; Thomas MacRury; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.

Authors:  Grant R Stenton; Lloyd F Mackenzie; Patrick Tam; Jennifer L Cross; Curtis Harwig; Jeffrey Raymond; Judy Toews; Joyce Wu; Nancy Ogden; Thomas MacRury; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.